Racura Oncology Experiences a Flat Day Amidst Broader Market Stagnation
On Friday 23 March 2026, Racura Oncology (ticker RAC.AX) closed the trading session unchanged, with a 0 % daily swing. The share price settled at AUD 1.53, a level that mirrors the 52‑week low recorded on 20 October 2026. Despite the lack of movement, the company’s market presence remains substantial, with a market capitalisation of AUD 206.7 million and 196.1 million shares outstanding.
Trading Activity and Historical Context
Over the past 24 hours, AUD 60.4 k worth of Racura shares changed hands, a modest volume compared with the company’s market size. This quiet session follows a pronounced decline in the preceding month, as Racura’s share price fell 24.27 % from the end of February to the present day. The simple moving average (SMA) over the last 200 trading days sits at AUD 2.32, indicating that current trading levels lie well below the longer‑term average. In contrast, the most recent 52‑week high of AUD 3.79 was reached on 17 November 2025, underscoring a significant contraction in investor sentiment.
Peer Comparison: A Snapshot of the Australian Market
Racura’s performance can be contextualised by examining the last‑hour movements of five other Australian stocks:
| Ticker | 24‑hour change | Current price (AUD) | Market cap (AUD mn) |
|---|---|---|---|
| MYR.AX (Myer) | 0 % | 0.20 | 239.8 |
| SGQ.AX (St George Mining) | -1.75 % | 0.05 | 244.5 |
| AS1.AX (Asara) | +4.35 % | 0.11 | 240.7 |
| SLS.AX (Solstice Minerals) | -2.93 % | 1.80 | 239.2 |
| ADH.AX (Adairs) | -4.04 % | 1.34 | 245.2 |
While some peers such as Asara posted a modest gain, the majority experienced declines, reflecting a broader trend of cautious trading across the Australian equity market.
Company Overview
Racura Oncology Ltd. is headquartered in Sydney and is listed on the ASX All Markets. The company concentrates its research on metastatic breast cancer and acute myeloid leukaemia, pursuing a dual‑focus strategy that couples anti‑cancer therapies with cardio‑protective measures. Racura’s global outreach is supported by its online platform at www.raceoncology.com . Despite the recent downward pressure on its stock, the firm continues to advance clinical programmes that could redefine treatment pathways for patients worldwide.
The information presented reflects data up to 07:43 AM Central Europe on Friday 23 March 2026 and is intended for informational purposes only.
